Department of Psychology, University of Mississippi, Oxford, MS, USA.
Headache. 2013 Mar;53(3):427-36. doi: 10.1111/head.12074. Epub 2013 Mar 7.
Four ongoing U.S. public health surveillance studies gather information relevant to the prevalence, impact, and treatment of headache and migraine: the National Health Interview Survey, the National Health and Nutrition Examination Survey, the National Ambulatory Care Survey, and the National Hospital Ambulatory Medical Care Survey. The American Migraine Prevalence and Prevention (AMPP) study is a privately funded study that provides comparative U.S. population-based estimates of the prevalence and burden of migraine and chronic migraine.
To gather in one place and compare the most current available estimates of the U.S. adult prevalence of headache and migraine, and the number of affected people overall and in various subgroups, and to provide estimates of headache burden and treatment patterns by examining migraine and headache as a reason for ambulatory care and emergency department (ED) visits in the United States.
We reviewed published analyses from available epidemiological studies identified through searches of PubMed and the National Center for Health Statistics. We aimed to identify information about migraine and headache burden, and treatment in national surveys conducted over the last decade. For each source, we selected the best available and most current estimate of migraine or headache prevalence, and selected associated measures of disability, health care use, and treatment patterns.
Compared with a slightly higher proportion of 22.7% in the National Health and Nutrition Examination Survey, 16.6% of adults 18 or older reported having migraine or other severe headaches in the last 3 months in the 2011 National Health Interview Survey. In contrast, the AMPP study found an overall prevalence of migraine of 11.7% and probable migraine of 4.5%, for a total of 16.2%. Data from National Ambulatory Medical Care Survey/National Hospital Ambulatory Medical Care Survey showed that head pain was the fifth leading cause of ED visits overall in the U.S. and accounted for 1.2% of outpatient visits. The burden of headache was highest in females 18-44, where the 3-month prevalence of migraine or severe headache was 26.1% and head pain was the third leading cause of ED visits. The prevalence and burden of headache was substantial even in the least affected subgroup of males 75 or older, where 4.6% reported experiencing severe headache or migraine in the previous 3 months. Triptans accounted for almost 80% of antimigraine analgesics prescribed at office visits in 2009, nearly half of which were for sumatriptan. Migraine is associated with increased risk for other physical and psychiatric comorbidities, and this risk increases with headache frequency.
This report provides the most current available estimates of the prevalence, impact, and treatment patterns of migraine or severe headache in the United States. Migraine and other severe headaches are a common and major public health problem, particularly among reproductive-aged women. Data about prevalence and disability from the major government-funded surveillance studies are generally consistent with results of studies such as the American Migraine Studies 1 and 2, and the AMPP study.
四项正在进行的美国公共卫生监测研究收集了与头痛和偏头痛的流行率、影响和治疗相关的信息:国家健康访谈调查、国家健康和营养检查调查、国家门诊护理调查和国家医院门诊医疗护理调查。美国偏头痛流行和预防(AMPP)研究是一项私人资助的研究,提供了美国偏头痛和慢性偏头痛流行率和负担的比较性基于人群的估计。
收集目前可用的美国成年人头痛和偏头痛流行率的最新估计值,以及总体和各种亚组中受影响人数的估计值,并通过检查偏头痛和头痛作为美国门诊护理和急诊就诊的原因,提供头痛负担和治疗模式的估计值。
我们通过在 PubMed 和国家卫生统计中心搜索,审查了已发表的可用流行病学研究的分析。我们旨在确定在过去十年进行的国家调查中关于偏头痛和头痛负担以及治疗的信息。对于每个来源,我们选择了偏头痛或头痛流行率的最佳和最新估计值,并选择了与残疾、医疗保健使用和治疗模式相关的相关措施。
与国家健康和营养检查调查中略高的 22.7%相比,2011 年国家健康访谈调查中,18 岁或以上的成年人报告在过去 3 个月内有偏头痛或其他严重头痛的比例为 16.6%。相比之下,AMPP 研究发现偏头痛的总体患病率为 11.7%,可能偏头痛的患病率为 4.5%,总计为 16.2%。国家门诊医疗保健调查/国家医院门诊医疗保健调查的数据显示,头痛是美国急诊科就诊的第五大常见原因,占门诊就诊的 1.2%。头痛的负担在 18-44 岁的女性中最高,其中偏头痛或严重头痛的 3 个月患病率为 26.1%,头痛是急诊科就诊的第三大常见原因。即使在偏头痛发病率最低的亚组(75 岁或以上的男性)中,偏头痛和头痛的流行率和负担也相当大,其中 4.6%的人报告在过去 3 个月内经历过严重头痛或偏头痛。曲坦类药物占 2009 年办公室就诊时开出处方的偏头痛镇痛药的近 80%,其中近一半是舒马曲坦。偏头痛与其他身体和精神共病的风险增加有关,并且这种风险随着头痛频率的增加而增加。
本报告提供了目前可用的美国偏头痛或严重头痛流行率、影响和治疗模式的最新估计值。偏头痛和其他严重头痛是一个常见且重大的公共卫生问题,尤其是在育龄妇女中。主要政府资助的监测研究中的患病率和残疾数据通常与美国偏头痛研究 1 和 2 以及 AMPP 研究等研究的结果一致。